Trellus Health Share Discussion Threads

[james188] 18/6/2021 18:47

I commented earlier on the Restricted Offer procedures for direct applicants, which I thought were pretty clunky.

Having not heard how many shares I had been allocated under the Restricted Offer, I called LINK today to find out what was going on. It was very unsatisfactory experience for a host of reasons and they had no record of my application or whether I had been issued any shares. Frankly, they were very polite, but clueless.

I e-mailed the company direct to ask what the hell was going on. Very impressively, the company secretary (Salim Hamir) called me back almost immediately to give me a very full explanation of the position and to confirm my share allocation. I cannot think of many companies who would bother to do that.

The admin behind the TRLS IPO has clearly been sub par, which is a real shame, given that the IPO itself has been so successful. I think that EKF and the companies that it has spun out are best in class in the way that they deal with retail investors.There are going to be further spin-outs. I think that lessons will be learnt from this one. I am posting this as I believe that there are still some applicants in the dark. The company is on the case.

[rivaldo] 16/6/2021 14:15

The Amati AIM VCT this afternoon released their monthly factsheet, and had this to say FYI:



"New investments were made in Trellus Health, an IPO spin out from Mount Sinai facilitated by EKF Diagnostics. Trellus is commercialising 20 years of research by the academic founders who created the GRITT programme to help irritable bowel disorder (IBD) patients increase their resilience to the social-mental and ultimately biological aspects of their disease. Evidence shows that IBD patients with greater resilience are better able to self-manage their symptoms and become a lower burden on the healthcare system. Trellus is developing an AI powered platform to on-board, assess and guide patients through the GRITT programme with the help of a small healthcare team as well as deploy the GRITT methodology into other chronic disease areas."

[wan] 16/6/2021 07:43

Trellus has a great team, including experienced leaders/founders with real passion, commitment, vision and a genuine mission to improve patients lives, which the following exemplifies -

Trellus Health Co-Founder, Dr. Marla Dubinsky MD, Receives Uniting to Care & Cure Award from CCF
Media Coverage | June 14, 2021
Trellus Health Co-Founder, Dr. Marla Dubinsky, MD, was recently honored with the 2021 Uniting to Care & Cure Award from the Crohn’s & Colitis Foundation (CCF).

The award recognizes healthcare providers who have shown exceptional dedication to the Inflammatory Bowel Disease (IBD) community of patients and caregivers, and for advancing the CCF mission to improve patient quality of life and find cures for IBD.

Full release -

[wan] 16/6/2021 07:34

Obviously IBD is a chronic condition, and we know that Trellus will also eventually abe offering personalised care for other complex/chronic conditions.

The following recent interview indicates that virtual chronic care management is accelerating, fuelled by the rapid adoption of telehealth -

The Clinic by Cleveland Clinic CEO points to telehealth's future
Frank McGillin talks about "on-demand" virtual care, virtual second opinions, chronic care management via telemedicine and telehealth personalization.
By
Bill Siwicki
June 14, 2021

Demand for "on-demand" telehealth services will grow, technology will normalize access to health experts via telemedicine, virtual chronic care management is growing and personalization will influence telehealth engagement.

Q: Do you believe demand for "on-demand" virtual care will grow? If so, why?

A: The horse is out of the barn for virtual care. COVID-19 eliminated many of the barriers to virtual care that existed before the pandemic, from provider reluctance to lack of infrastructure to hesitance from consumers.

Now, people are finding that they like the convenience of virtual care – especially when they can get it on demand. One physician-consumer survey found more than half of consumers plan to use telehealth more after the pandemic than they did beforehand, while 92% of physicians expect to continue providing virtual care.

Q: What is the outlook for virtual chronic care management?

A: Virtual chronic care management is accelerating. It's a trend fueled not only by the rapid adoption of telehealth, but also the creative use of remote patient monitoring technologies to monitor and manage individuals' health.

Full article -

[wan] 14/6/2021 06:42

With perhaps some relevance to the above post, a couple of slides from EKF's 2021 – 2024 Growth Strategy that in my opinion also has some relevance here -

2. Exploit newly expanded capabilities to meet the demand for
contract manufacturing services
Leverage relationship with private sector partner to support their diagnostics strategy
EKF currently makes kits for their COVID sample collection product in USA,
UK and Germany
Customer is the largest distribution business in the world
Leveraging distribution business to move into ‘home diagnostics’
EKF perfect partner due to manufacturing capabilities in US, Europe and UK
EKF also a key regulatory partner
Collaborating on new molecular enzyme product to be made in Elkhart
Reliant on EKF for all diagnostic advice
Increasing demand for kit manufacturing
Substantial revenue and EBITDA growth opportunity

3. Seek complementary earnings-enhancing acquisitions with
key strategic value to the core business
Three growth areas identified

CLIA lab for diagnostic tests
– Further area of partnership with global private sector partner
– Potential to link to Trellus, Renalytix and Verici
– Move into $4bn US diagnostic testing market which has forecast CAGR of 13% from 2021 to 2027

Molecular assay and platform
– Plug and play assays providing simplified workflows and cost-effective logistics
– In-house molecular assays and development of assays for major platform providers
– Potential Point Of Care (POC) molecular instrument

Expansion of kitting capabilities
– Contract manufacturing for existing diagnostics companies
– Adding to our existing capabilities in USA, UK and Germany

[wan] 11/6/2021 11:06

Food for thought (given EKF's connection with a very large private sector partner)-

Amazon attracting multiple companies to telehealth service
An Amazon exec said that the organization has had "quite a bit of interest from other companies in using this service," according to CNBC.
By
Kat Jercich
June 10, 2021

Amazon Care has signed several companies to its telehealth service, an executive said during a Wall Street Journal event on Wednesday, as the consumer giant continues with plans to roll out the service to all 50 states by this summer.

Speaking at the WSJ Tech Health event, Amazon VP Babak Parviz said that "we’ve had quite a bit of interest from other companies in using this service," according to CNBC.

"We are planning to expand the digital component of this in the next few months to every state in the U.S.," said Parviz. "We'll also make it available to other company employees, besides Amazon, to use this, should they choose to sign up and use the service.

"The plan is to expand the service nationwide," he said.

ON THE RECORD

"Amazon Care is a healthcare service that is 'cyber physical' – it's hybrid. It's part digital, part physical," said Parviz.

"It’s quite different from anything we’ve had in the past," he added.

Full story -

[wan] 02/6/2021 07:49

Most readers will now be familiar with Trellus Health's Technology platform and intellectual property. So just as a quick reminder, the Company’s connected health solution will be enabled through an integrated suite of technology and IP to enable scalable remote access for the Company’s care team, patients, and their health care providers, which importantly is not limited to IBD.

The primary components of the Company’s connected health solution include:
(1) TrellusElevateTM platform
(2) HIPAA-Compliant telehealth platform
(3) GRITTTM resilience assessment and personalised care plans
(4) Quad4XTM risk stratifier
(5) Digital education and behavioural tools
(6) Remote patient monitoring of symptoms, biomarkers, behaviours

And to just underscore that; Trellus secured an exclusive license from ISMMS to commercialise the patentpending GRITT™ methodology across seven chronic disease categories.

While the original GRITTTM resilience assessment was developed specifically for the IBD population, the Company considers that it can be adapted to other chronic conditions with minor refinements.

The following is a sponsored article, thus it provides both a relevant flavour and notable insights into the large and rapidly developing telehealth opportunity, not to mention that part of Trellus Health's business model includes sharing healthcare savings, which even at this early stage of telehealth adoption, appears to be substantial-

The next frontier in specialty care: How telehealth is expanding its reach by making it more accessible, affordable, and higher quality

By Dr. Keith H. Bachman – Kaiser Permanente
Jun 1, 2021

Few things can impact employer health care costs like specialty care needs. This broad category of advanced medical care deals with treatment-intensive conditions such as heart disease, depression, and cancer just to name a few. So, it makes sense that employers should always take a long look at the value of any provider’s specialty care services, especially in light of rising health care costs.

But employers may be surprised to learn that there’s a new differentiating factor that can help evaluate top-notch specialty care: telehealth.

This new virtual specialty care horizon came into sharp focus during the pandemic-driven growth and consumer acceptance of telehealth over the last year—by some estimates, telehealth use jumped more than 3,000% in 2020. And consider this: prior to Covid-19, less than 40% patients with a chronic condition had a telehealth visit. That number now stands at 60%. Just as notable: 53% patients of patients with a chronic condition now say that telehealth provided the same or better quality of care as an in-person visits, versus just 28% general population.

Employers should also note a recent a Government Accountability Office study of Medicare Advantage plans revealed that telehealth services helped to save $500 million in costs. A further study by Anthem found savings of more than $200 per care interaction due to telehealth efficiencies, including helping to reduce redundant tests and unnecessary medications, all without a dip in the quality of care.

Virtual care also has the potential to greatly improve access to advanced care in rural counties, where it may otherwise be lacking. Now specialists are freed up to provide care across a wide geographic area, saving travel time and expense. And If a patient needs to move an appointment, it can be reset quickly with no need to wait till the provider’s next trip to a patient’s area.

Full story -

[davr0s] 01/6/2021 16:33

Ugh - I've got a naff sized position. Hardly cover the trading costs lol

[luffness] 01/6/2021 14:54

Spoke to HL not applied yet but allocations were 6.5% of applications apparently

[adobbing] 01/6/2021 13:38

Just checked my Interactive Investors account and can now see what I got.
My £1000 pledge should have got me 2500, I got just 162, but these do now appear as tradeable.
The balance has been returned to the account as cash and so I’ve just bought £1000 worth for 70.4p

Just in case any other II holders were wondering what had happened.

[nimbo1] 01/6/2021 13:38

Hi wan - good to see you here. In a moment of madness I didn't own EKF before the ex div in specie date for trellus so have been begun buying a stake in the open market.

TAM clearly huge - and out of interest listing market value is the same cap as renx when it listed on aim...

[wan] 01/6/2021 07:31

Trellus Health has been a long time in the making; hence the Trellus offering is already 'scientifically validated'. They have assembled (and attracted) a highly experienced leadership team which is supported by an equally impressive Scientific Advisory Board, comprising ten pre-eminent experts.

With compelling health economics and societal benefits, an attractive business model that also includes negotiated shared cost savings, rapid expected commercialisation, with initial revenue in 2021 through demonstration projects, the platform appears set for success.

With some very large companies already taking the initiative and deploying, at the employee level, their own healthcare offerings, including some that are trialling and 'demonstrating' before a wider roll-out, Trellus might indeed accelerate very quickly out of the demonstration starting blocks!

A good example of employers taking the initiative and trialling -

Amazon’s Multichannel Bid To Bring ‘Amazon Effect’ To Healthcare
28th May 2021

Those reports, in turn, follow March announcements that it will expand its telehealth service, Amazon Care, to employees in all 50 states starting this summer. It also plans to make the service available to other employers later this year. That service, as it stands now, focuses on telehealth consultations and in-home visits from nurses for a fee.

Amazon, it seems, is more determined than ever to shoulder its own push into healthcare on its own terms, with select partnerships that augment the ecosystem already in place. Earlier this year, the joint efforts between Amazon, Berkshire Hathaway and JPMorgan Chase — Haven, which sought to, among other things, make insurance benefits easier to understand — was disbanded. The platform, and the algorithm, the pricing power and the logistics and the last mile all seem, at least in Amazon’s eyes, to be enough to disrupt healthcare.



Beyond demonstration - We know that the like of Amazon has designs beyond their own employees, and after building their own lab and trialling diagnostic testing on their own employees, they will be rolling out a much wider offering, which is very likely to be diagnostic testing beyond COVID-19 -

Amazon diagnostic lab receives College of American Pathologists accreditation

Accreditation is awarded to laboratories that meet stringent requirements for quality and safety.
Amazon's diagnostics laboratory in Hebron, Kentucky, has received accreditation from the College of American Pathologists (CAP). Widely recognized as an industry gold standard, the CAP Laboratory Accreditation Program is designed to ensure laboratories meet stringent requirements and maintain the highest standards of laboratory quality, safety, and accuracy. The laboratory—which processes thousands of COVID-19 tests a day—is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), which regulate laboratory testing in the U.S.

"From day one of launching our employee COVID-19 testing program, we have focused on achieving the highest standards of quality and safety for our diagnostics laboratory," said Cem Sibay, Vice President, Amazon. "We are thrilled to receive this accreditation from the College of American Pathologists and are committed to delivering quality results and ensuring employee well-being."

Amazon received the CAP accreditation following a rigorous application and review process, including a multi-day on-site review by a CAP inspector. The inspector examined laboratory processes to ensure accuracy in diagnostic results and verified that the highest standards are in place to promote employee safety. The inspection also included a thorough review of the laboratory's quality control procedures and employee training records, in addition to interviews with technologists and laboratory management.

The Kentucky laboratory was built in response to the COVID-19 pandemic to help ensure the health and safety of our frontline employees by providing them with regular, reliable access to free COVID-19 testing. In April 2020, we quickly responded to the pandemic and began assembling a team with a variety of skills—from research scientists and program managers to procurement specialists and software engineers—to focus on supporting a comprehensive COVID-19 testing program. The initiative included building state-of-the-art diagnostic laboratories in the U.S. and UK, and ultimately creating an in-house COVID-19 testing program from scratch. Within weeks of launching, the laboratories were processing thousands of tests per day and building incremental testing capacity. The labs have now processed millions of voluntary tests from over 750,000 of our frontline employees, making Amazon a leader in employer-driven COVID-19 testing -

[james188] 29/5/2021 20:29

I completely understand that the focus was to avoid a flop and make sure that the float was successful. That said, it is obvious now (and equally would have been in advance), that demand for the shares massively outstripped supply. It seems likely that allocations for PIs will be relatively derisory and frankly not worth the effort involved - a real slog for the likes of me who could not apply other than direct with all the admin that that entailed. It was very time consuming.

Like others, I have no idea when the balance payment that I made for shares which have been scaled back will be recredited to my account. Nor do I know how many shares I was allocated last Friday. That money has been dead for over one week and counting. I do not think that PIs were treated at all well. The company (here meaning EKF as the driving force behind all of this) needs to do much better than this in the future.

[bscuit] 29/5/2021 19:25

The reason for the low allocation was that the Restricted Shareholder offer was limited to £0.9Million. I didn’t spot that or else I would have applied in the main placing.

[luffness] 29/5/2021 07:58

Good to know they have consistency of staff! What proportion did you get?

[wan] 29/5/2021 07:52

My experience was very straight forward, having also selected the request for a call-back (rather than wait), and I subsequently received phone call a short while afterwards (within around 10 minutes). I did not need a certificate number nor an account number.

[luffness] 29/5/2021 06:46

Yeah good luck with that firstly you wait 20mins to speak to someone then they simply read the offer details and then don't understand what an allocation basis is. They might help if you know the certificate number (how?) or you account number (how many people have a designated account?).

[wan] 29/5/2021 04:29

I had other commitments/engagements yesterday afternoon, otherwise I would have reminded investors of the following -

EKF Diagnostics Holdings PLC Trellus Health plc: Successful Restricted Offer
26/05/2021

Applicants to the Restricted Offer can confirm their final allotment of shares by contacting the Link Group helpline on 0371 664 0321. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. The helpline is open between 9.00 a.m. and 5.30 p.m., Monday to Friday excluding public holidays in England and Wales. The helpline cannot provide any financial, legal or tax advice and calls may be recorded and monitored for security and training purposes.

[boadicea] 28/5/2021 20:17

The information on this share issue is full of holes. (They should have called it Trellis.)